Is retatrutide a biologic? Inside Eli Lilly's fight with the FDA

What the FDA decided, and why it matters

In 2024, the FDA classified retatrutide as a drug rather than a biological product. That sounds like a paperwork distinction. It is not. Drugs are approved through a new drug application (NDA) and get five years of market exclusivity. Biologics are approved through a biologics license application (BLA) and get twelve. For a molecule that could sell at Zepbound or Wegovy scale, that seven-year gap is worth tens of billions of dollars.

Eli Lilly disagreed with the FDA's call and sued. The case has been working through federal court since September 2024, and it is still not resolved. For background on retatrutide itself, the drug's mechanism, and its trial results, see what is retatrutide.

The dispute: 39 amino acids and a bright-line rule

The FDA's reasoning came down to a specific number. Under federal law, a biological product includes a "protein," and the FDA has used a bright-line rule: a molecule needs more than 40 amino acids in a single chain to count. Retatrutide's main backbone runs 39 alpha amino acids, one short. It connects to a second, shorter chain through an isopeptide bond, but the FDA counted only the primary backbone and ruled that retatrutide falls outside the definition of protein, and therefore outside the biologic pathway.

Lilly argued the FDA's math was too narrow, that retatrutide is "analogous to" a protein under the statute even if it does not clear the bright-line count on a technicality, and filed suit in the Southern District of Indiana in September 2024 to force a different reading.

The September 2025 ruling

On September 30, 2025, Judge Tanya Walton Pratt sided with Lilly, at least in part. She ruled that the FDA's narrow interpretation of "analogous to a protein" was arbitrary and capricious, and vacated the agency's drug classification. That was a real win for Lilly.

But the ruling stopped short of what Lilly actually wanted. Pratt did not order the FDA to classify retatrutide as a biologic. She remanded the question, sending it back to the agency to apply a better-reasoned standard and decide again. That left the door open for the FDA to arrive at the same conclusion through a more defensible process, which is not the outcome Lilly is after.

Lilly's appeal, and what's actually at stake

In February 2026, Lilly appealed to the Seventh Circuit, asking the appeals court to go further than the district court did and order the FDA to classify retatrutide as a biologic outright, rather than sending the fight back to the agency for another round. Oral arguments are scheduled for September 24, 2026.

The exclusivity math is the headline number, but it is not the only thing riding on this. Biologic status also determines how future competitors challenge retatrutide once it is on the market: through the biosimilar pathway, which is slower and more expensive to litigate than the generic drug challenges that follow an NDA. For a look at how that fight has played out with a molecule that already has generic challengers lined up, see generic tirzepatide's FDA timeline.

What this means for compounded retatrutide

Retatrutide has no legal source outside a clinical trial today, and that does not change no matter how the classification fight resolves. What the ruling decides is the situation after approval. Federal law excludes biological products from the 503A and 503B compounding exemptions that let pharmacies prepare drugs like semaglutide and tirzepatide during their shortages. If retatrutide ends up classified as a biologic, that compounding pathway is closed permanently, by statute, not by an FDA policy choice that could later shift.

If it stays classified as a drug, compounding stays theoretically possible under the same conditions that govern compounded tirzepatide now: a documented clinical need, and only if retatrutide ever lands on an FDA shortage or bulks list. That is a real difference for anyone tracking whether a cheaper, compounded version might eventually exist. For the current rules on that front, see is compounded tirzepatide legal in 2026, and for the risk profile of unregulated retatrutide sold today outside any legal channel, see retatrutide and BPC-157: the stack people ask about.

Where the trial data stands while the lawsuit plays out

None of this litigation touches the clinical results, which have kept landing well for Lilly. The TRIUMPH Phase 3 program has reported weight loss up to 28.3% at 80 weeks in adults with obesity, and separate trials have shown meaningful results in type 2 diabetes and knee osteoarthritis linked to excess weight. See TRIUMPH-2 and TRIUMPH-3 results for the diabetes and cardiovascular populations, and retatrutide vs tirzepatide for how the two drugs compare on the numbers so far.

When retatrutide might actually reach the market

Lilly has said it plans to submit its regulatory application in the first quarter of 2027, once it finishes the chemistry, manufacturing, and controls package, and that timeline holds regardless of what the Seventh Circuit decides in September. A BLA or an NDA both go through standard FDA review, which typically takes 10 to 12 months after submission. Assuming no delays, a realistic approval window lands in late 2027 or 2028.

The classification fight will likely be settled well before then, since oral arguments are set for September 2026 and Lilly is not planning to file until early 2027. Whichever way it goes, it will already be decided by the time retatrutide's application actually reaches the FDA's desk, which makes this fall's ruling the thing worth watching now, not the approval itself.